In response to the increased demand for COVID-19 therapeutics, the HHS Administration for Strategic Preparedness and Response transitioned to a State and Territory-coordinated Distribution System on September 13, 2021. To find out how many patient courses of COVID-19 therapeutics are being distributed to your state or territory, please see the current distribution tables.
View More
REGEN-COV was distributed by the federal government to states, territories, and federal entities from November 2020 through February 2021.
Distribution Weeks:
- Distribution Cycle 1 - Week 1: November 24 - December 1, 2020
- Distribution Cycle 2 - Week 2: December 2 -8, 2020
- Distribution Cycle 3 - Week 3: December 9-15, 2020
- Distribution Cycle 4 - Week 4: December 16-22, 2020
- Distribution Cycle 5 - Weeks 5-6: December 23, 2020 - January 5, 2021
- Distribution Cycle 6 - Weeks 7-8: January 6 - 19, 2021
- Distribution Cycle 7 - Weeks 9-10: January 19 - February 2, 2021
States / Territories / Federal Entities |
Total
Patient Courses
Allocated |
Week 1
Phase 1 (patient courses) |
Week 2 Phase 1 (patient courses) |
Week 3
Phase 1
(patient courses) |
Week 4
Phase 1 (patient courses) |
Week 5-6
Phase 2 (patient courses) |
Week 7-8
Phase 2 (patient courses) |
Week 9-10
Phase 2 (patient courses) |
All Jurisdictions (patient courses) |
147,902 |
36,072 |
26,440 |
14,750 |
16,320 |
26,428 |
12,708 |
15,184 |
Alabama |
2,014 |
456 |
330 |
180 |
180 |
508 |
170 |
190 |
Alaska |
316 |
96 |
80 |
30 |
30 |
40 |
20 |
20 |
American Samoa |
10 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
Arizona |
3,550 |
720 |
550 |
320 |
400 |
710 |
340 |
510 |
Arkansas |
1,444 |
384 |
270 |
130 |
130 |
250 |
120 |
160 |
Bureau of Prisons |
336 |
0 |
0 |
0 |
0 |
192 |
72 |
72 |
California |
15,308 |
2,328 |
2,160 |
1,240 |
1,380 |
4,120 |
1,620 |
2,460 |
Colorado |
2,450 |
960 |
640 |
250 |
250 |
100 |
110 |
140 |
Commonwealth of the Northern Mariana Islands |
10 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
Connecticut |
1,404 |
384 |
250 |
140 |
140 |
240 |
90 |
160 |
Delaware |
446 |
96 |
80 |
50 |
50 |
90 |
30 |
50 |
Department of Defense |
3,116 |
216 |
400 |
1,000 |
1,000 |
300 |
100 |
100 |
Departmentof Health and Human Services |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Department of State |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
District of Columbia |
208 |
48 |
40 |
20 |
20 |
40 |
20 |
20 |
Federated States of Micronesia |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Florida |
6,658 |
1,608 |
1,220 |
560 |
560 |
1,210 |
630 |
870 |
Georgia |
3,574 |
744 |
520 |
290 |
340 |
720 |
410 |
550 |
Guam |
50 |
0 |
10 |
10 |
10 |
10 |
10 |
0 |
Hawaii |
114 |
24 |
20 |
10 |
10 |
20 |
10 |
20 |
Idaho |
790 |
240 |
170 |
80 |
80 |
120 |
40 |
60 |
Illinois |
6,160 |
2,280 |
1,330 |
550 |
550 |
800 |
270 |
380 |
Indiana |
4,228 |
1,248 |
820 |
370 |
370 |
600 |
570 |
250 |
Indian Health Service |
4,416 |
216 |
400 |
1,000 |
1,000 |
600 |
600 |
600 |
Iowa |
1,684 |
744 |
370 |
130 |
130 |
160 |
60 |
90 |
Kansas |
1,726 |
576 |
360 |
150 |
150 |
250 |
100 |
140 |
Kentucky |
2,830 |
840 |
590 |
270 |
270 |
450 |
190 |
220 |
Louisiana |
4,168 |
456 |
280 |
160 |
160 |
1,630 |
902 |
580 |
Maine |
228 |
48 |
30 |
20 |
20 |
40 |
20 |
50 |
Maryland |
1,878 |
528 |
380 |
180 |
180 |
290 |
130 |
190 |
Massachusetts |
1,964 |
504 |
340 |
230 |
240 |
450 |
200 |
0 |
Michigan |
4,342 |
1,512 |
1,110 |
420 |
420 |
530 |
160 |
190 |
Minnesota |
2,872 |
1,152 |
750 |
260 |
260 |
270 |
80 |
100 |
Mississippi |
1,272 |
312 |
240 |
120 |
120 |
240 |
110 |
130 |
Missouri |
2,812 |
1,032 |
610 |
240 |
240 |
390 |
150 |
150 |
Montana |
664 |
264 |
150 |
60 |
60 |
70 |
20 |
40 |
National Institute of Health |
|
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Nebraska |
1,146 |
456 |
260 |
100 |
100 |
120 |
40 |
70 |
Nevada |
1,582 |
432 |
340 |
150 |
150 |
280 |
100 |
130 |
New Hampshire |
392 |
72 |
60 |
40 |
50 |
80 |
40 |
50 |
New Jersey |
3,466 |
864 |
680 |
320 |
320 |
570 |
220 |
492 |
New Mexico |
1,162 |
432 |
240 |
100 |
100 |
150 |
60 |
80 |
New York |
6,244 |
1,224 |
1,100 |
580 |
580 |
1,180 |
600 |
980 |
North Carolina |
3,378 |
696 |
530 |
270 |
300 |
782 |
320 |
480 |
North Dakota |
520 |
240 |
120 |
40 |
40 |
40 |
20 |
20 |
Ohio |
6,010 |
1,680 |
1,320 |
560 |
640 |
990 |
350 |
470 |
Oklahoma |
2,812 |
696 |
520 |
210 |
210 |
400 |
546 |
230 |
Oregon |
816 |
216 |
180 |
80 |
80 |
130 |
50 |
80 |
Palau |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Pennsylvania |
5,518 |
1,368 |
1,130 |
570 |
590 |
1,060 |
360 |
440 |
Puerto Rico |
340 |
0 |
100 |
40 |
40 |
80 |
30 |
50 |
Republic of Marshall Islands |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Rhode Island |
598 |
168 |
110 |
60 |
60 |
90 |
40 |
70 |
South Carolina |
1,644 |
312 |
220 |
140 |
150 |
310 |
242 |
270 |
South Dakota |
590 |
240 |
140 |
50 |
50 |
60 |
20 |
30 |
Tennessee |
3,520 |
840 |
630 |
280 |
370 |
830 |
270 |
300 |
Texas |
12,126 |
2,784 |
1,850 |
830 |
1,850 |
2,116 |
1,216 |
1,480 |
U.S. Virgin Islands |
60 |
0 |
10 |
10 |
10 |
10 |
10 |
10 |
Utah |
1,612 |
552 |
290 |
140 |
140 |
220 |
100 |
170 |
Vermont |
94 |
24 |
10 |
10 |
10 |
10 |
10 |
20 |
Veterans Health Administration |
3,016 |
216 |
400 |
1,000 |
1,000 |
300 |
0 |
100 |
Virginia |
2,126 |
456 |
360 |
170 |
200 |
380 |
190 |
370 |
Washington |
1,192 |
312 |
320 |
140 |
140 |
180 |
100 |
0 |
West Virginia |
972 |
192 |
150 |
70 |
70 |
140 |
270 |
80 |
Wisconsin |
3,550 |
1,440 |
790 |
290 |
290 |
430 |
130 |
180 |
Wyoming |
374 |
144 |
80 |
30 |
30 |
40 |
20 |
30 |
Current Total Monoclonal Antibody Therapeutics Allocated and Delivered
Therapeutic |
Total Allocation (patient courses) |
Total Delivered (patient courses) |
Bamlanivimab (through March 2, 2021) |
798,591 |
664,691 |
REGEN-COV (through February 2, 2021) |
147,902 |
96,923 |
All Monoclonal Antibody Therapeutics |
946,493 |
761,614 |
Allocation Phases
- Phase 1: allocation to hospitals and hospital-affiliated locations
- Phase 2: allocation expanded to additional outpatients facilities
Prior COVID-19 Therapeutic Product Efforts
Date Range |
Threshold/Distribution/Allocation by Jurisdiction |
April 25, 2022 - April 30, 2023
|
COVID-19 Therapeutics Threshold Determinations
|
September 13, 2021 - April 24, 2022 |
COVID-19 Therapeutics Distribution |
November 9, 2020 - March 2, 2021 |
Bamlanivimab Distribution |
July 6, 2020 - October 4, 2020 |
Allocation of Commercial Veklury (Remdesivir) (PDF) |
May 4, 2020 - June 29, 2020
|
Allocation of Donated Veklury (Remdesivir)
|